Beyond The Obvious Differences Between In-Person And Virtual Pitching

Markus Warmuth, M.D., CEO, Monte Rosa Therapeutics, notes it being more difficult to discern how your story is coming across when pitching virtually. Joined by fellow panelists, Keith Vendola, M.D., CSO and head of strategy at Rezolute; and Josh Brumm, CEO of Dyne Therapeutics; the three share some best practices for overcoming some of the limitations virtual pitching provides. This is part of a larger executive virtual roundtable (EVR) (view full video here) on Pitching And Fundraising In The New Norm.